MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS
Clinical trials for MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS explained in plain language.
Never miss a new study
Get alerted when new MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS trials appear
Sign up with your email to follow new studies for MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy battle for blood cancer patients
Disease control OngoingThis study tests whether adding another drug (lenalidomide or vorinostat) to the standard chemotherapy azacitidine works better than azacitidine alone for people with higher-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). About 282 adults with thes…
Matched conditions: MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 02:06 UTC
-
Experimental drug TAK-243 targets Hard-to-Treat blood cancers
Disease control TerminatedThis early-stage trial tests the safety and best dose of TAK-243 in about 42 adults with acute myeloid leukemia or myelodysplastic syndromes that have returned or are not responding to standard therapy. TAK-243 works by blocking enzymes that cancer cells need to grow. The study i…
Matched conditions: MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 02:04 UTC
-
New drug combo shows promise for blood cancers in early trial
Disease control OngoingThis study tested a combination of two drugs, vorinostat and azacitidine, in 135 people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The goal was to find the safest dose and see how well the drugs work together to stop cancer cell growth. Participants rece…
Matched conditions: MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 08, 2026 12:03 UTC
-
New drug combo aims to improve leukemia treatment
Disease control OngoingThis phase 2 trial tests whether adding venetoclax to ASTX727 (a two-drug pill) works better than ASTX727 alone for adults with chronic myelomonocytic leukemia or related bone marrow cancers with excess blasts. About 132 participants will receive either the combination or ASTX727…
Matched conditions: MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 07, 2026 18:42 UTC